Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.
Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.
AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.
A new study examined diabetes as an independent predictor of heart failure.
Reduces risk for heart failure and cardiovascular disease hospitalizations.
Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.